NVST Envista Holdings Corp
Data as of close
Healthcare · Dental Equipment & Supplies
Envista Holdings Corp (NVST) is a healthcare company in the Dental Equipment & Supplies industry, with a market capitalization of $4.0 billion. Shares last traded at $24.71, 18.6% below their 52-week high. Over the past year the stock is up 22.6%. NVST trades at a price-to-earnings ratio of 41.78, above the Healthcare median of 26.97. Net profit margin is 3.3%, above the peer median of -1.3%. Revenue grew 8.3% year over year.
* P/E (TTM) = market cap ÷ net income over the trailing twelve months where four consecutive quarters are reported, otherwise the latest fiscal year — the same basis as the peer table and the screener, so it can differ from price ÷ EPS.
Performance
Chart
Full chart →Daily candles · volume · SMA(20)/SMA(50) · Databento EQUS.MINI.
Technicals
Financials
Trailing twelve months where four consecutive quarters are reported, otherwise the latest fiscal year; revenue is the fiscal-year figure where quarterly revenue covers under half of it (typical for banks, insurers and REITs), and margins are taken on it; latest reported period ends 2026-07-03. Source: SEC EDGAR/XBRL.
Recent earnings
| Period | EPS (diluted) | Reported |
|---|---|---|
| Q2 2026 | $0.33 | 2026-08-05 |
| Q1 2026 | $0.23 | 2026-05-06 |
| Q4 2025 (derived) | $0.20 | 2026-02-12 |
| FY 2025 | $0.28 | 2026-02-12 |
| Q3 2025 | -$0.18 | 2025-10-30 |
| Q2 2025 | $0.16 | 2025-07-31 |
Q4 marked "derived" = fiscal-year EPS minus Q1–Q3 (10-Ks report only the annual figure); EPS is not strictly additive, so it can differ by a cent or two from the issuer's own Q4.
Healthcare peers
NVST vs 14 sector peers (Healthcare), by market cap. Data as of close
| LLY | Lilly (Eli) | $1.33T | 48.13 | 15.35 | 31.9% | -0.28% |
| JNJ | Johnson & Johnson | $652.2B | 40.52 | 6.57 | 16.2% | -0.82% |
| ONC | Beone Medicines Ltd. | $533.8B | 814.05 | 87.09 | 10.7% | -2.48% |
| ABBV | AbbVie | $510.3B | 80.87 | 7.93 | 9.8% | -2.05% |
| MRK | Merck | $366.4B | 115.46 | 5.50 | 4.8% | -0.22% |
| TMO | Thermo Fisher Scientific | $253.0B | 35.77 | 5.34 | 14.9% | -2.03% |
| AMGN | Amgen | $251.7B | 28.78 | 6.61 | 23.0% | -0.13% |
| GILD | Gilead Sciences | $211.3B | — | 6.82 | -12.5% | -0.23% |
| KLAC | KLA Corporation | $198.1B | 37.67 | 13.65 | 36.2% | -3.68% |
| ABT | Abbott Laboratories | $192.1B | 30.61 | 4.26 | 13.9% | +3.81% |
| PFE | Pfizer | $175.0B | 40.41 | 2.75 | 6.8% | +0.69% |
| DHR | Danaher Corporation | $160.5B | 37.05 | 6.27 | 16.9% | -1.80% |
| ISRG | Intuitive Surgical | $151.5B | 51.23 | 13.08 | 25.5% | +1.13% |
| VRTX | Vertex Pharmaceuticals | $144.5B | 32.80 | 11.48 | 35.0% | +1.96% |
Source: SEC EDGAR (fundamentals/EPS/dividends) · Databento EQUS.MINI (prices) · market cap & yield computed by tradmap. Informational only — not financial advice.